⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DNLI News
Denali Therapeutics Inc. Common Stock
Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
globenewswire.com
DNLI
Form 8-K
sec.gov
DNLI
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
globenewswire.com
DNLI
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
globenewswire.com
DNLI
Form 8-K
sec.gov
DNLI
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
globenewswire.com
DNLI
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
globenewswire.com
DNLI
Form 8-K
sec.gov
DNLI
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
globenewswire.com
DNLI
Form 8-K
sec.gov
DNLI
BIIB